Trinity Biotech (TRIB)
(Delayed Data from NSDQ)
$2.17 USD
-0.33 (-13.20%)
Updated Aug 28, 2024 03:55 PM ET
After-Market: $2.11 -0.06 (-2.76%) 7:46 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
TRIB 2.17 -0.33(-13.20%)
Will TRIB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TRIB
Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout
TRIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TRIB
Trinity Biotech Raises 2024 Revenue Forecast
Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales
Market Today: Nvidia's Anticipated Earnings, Trump Media's Stock Registration, and More
Trinity stock soars post-market on raised guidance, increased capacity